CYFRA 21-1 as a marker for colorectal cancer
AssigneeRoche Diagnostics Operations, Inc.
InventorsJohann Karl, Herbert Andres, Veit Peter Grunert, Wolfgang Rollinger, Werner Zolg
Life of this patent
Estimating the term…
Abstract
The present invention relates to the assessment of colorectal cancer. It discloses the use of the CYFRA 21-1 assay in the assessment of colorectal cancer. It also relates to a method for assessing colorectal cancer in vitro using a liquid sample, derived from an individual by measuring CYFRA 21-1 in said sample. Measurement of CYFRA 21-1 can, e.g., be used in the early detection or in the follow-up of patients with colorectal cancer.
Claims3
A method for assessing colorectal cancer in a sample from a patient wherein the sample is a bodily fluid sample selected from the group consisting of blood, serum, plasma, urine, saliva, and synovial fluid, the method comprising the steps of:
- measuring in said sample a concentration of a fragment of cytokeratin 19 (CYFRA 21-1) and a concentration of at least one low sensitivity marker for colorectal cancer,
- combining the concentrations to form a combined marker concentration, and
- correlating the combined marker concentration to the diagnosis of colorectal cancer.
Dependencies are inferred from the claim text.